



US008815955B2

(12) **United States Patent**  
**Roberts**

(10) **Patent No.:** **US 8,815,955 B2**  
(45) **Date of Patent:** **Aug. 26, 2014**

(54) **METHOD OF TREATING OCULAR DISORDERS**

- (75) Inventor: **Richard Roberts**, Johnston, IA (US)
- (73) Assignee: **Kemin Industries, Inc.**, Des Moines, IA (US)
- (\* ) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 207 days.

(21) Appl. No.: **13/238,939**

(22) Filed: **Sep. 21, 2011**

(65) **Prior Publication Data**

US 2012/0070422 A1 Mar. 22, 2012

**Related U.S. Application Data**

(60) Provisional application No. 61/384,958, filed on Sep. 21, 2010.

(51) **Int. Cl.**

- A61K 31/07* (2006.01)
- A61K 31/34* (2006.01)
- A61K 31/355* (2006.01)
- A61K 31/35* (2006.01)
- A61K 33/24* (2006.01)
- A61K 36/00* (2006.01)

(52) **U.S. Cl.**

USPC ..... **514/725; 514/474; 514/458; 514/734; 424/617; 424/725**

(58) **Field of Classification Search**

USPC ..... **514/725, 474, 458, 734; 424/617, 725**  
See application file for complete search history.

(56) **References Cited**

**U.S. PATENT DOCUMENTS**

2007/0082064 A1\* 4/2007 Krawitz ..... 424/638

**OTHER PUBLICATIONS**

- Richer, et al, Double-masked, placebo-controlled, randomized trial of lutein and antioxidant supplementation in the intervention of atrophic age-related macular degeneration: the Veterans LAST study (Lutein Antioxidant Supplementation Trial). 2004, vol. 75, No. 4, pp. 216-230.
- Areds, A Randomized, Placebo-Controlled, Clinical Trial of High-Dose Supplementation With Vitamins C and E and Beta Carotene for Age-Related Cataract and Vision Loss. AREDS Report No. 9. Arch Ophthalmol. 119:1439-1452, 2001.
- Seddon, J., et al., Dietary Carotenoids, Vitamins A, C, and E, and Advanced Age-Related Macular Degeneration. 1994, JAMA 272:1413-1420.
- Barker, F., et al., Nutritional Manipulation of Primate Retinas, V: Effects of Lutein, Zeaxanthin, and n-3 Fatty Acids on Retinal Sensitivity to Blue-Light-Induced Damage. 2011, Invest Ophthalmol Vis Sci. 52:3934-3942.
- Wooten B., et al., Macular pigment: influences on visual acuity and visibility. 2002, Prog Retinal and Eye Res. 21:225-240.
- Richer, et al., 2004; Stringham J. and Hammond B, The Glare Hypothesis of Macular Pigment Function. 2007, Optom Vis Sci. 84:858-864.
- Stringham J., et al., Macular Pigment and Visual Performance Under Glare Conditions. 2008, Optom Vis Sci. 85:82-88.


(Continued)

*Primary Examiner* — Rosanne Kosson

(74) *Attorney, Agent, or Firm* — Davis, Brown, Koehn, Shors & Roberts, P.C.; Kent A. Herink

(57) **ABSTRACT**

A method wherein subjects having or at risk for having hyperopia, presbyopia or astigmatism are administered a composition having an effective amount of ocular antioxidants, including specifically macular pigments, to prevent, treat, or delay the onset of age-related macular degeneration (AMD).



**13 Claims, 4 Drawing Sheets**